All News | FDA

Advertising & Promotion

Sep 14, 2021
OPDP Researchers Continue Secondary and Biosimilar Disclosure Studies, Detail Other Research Results
Sep 8, 2021
Federal Enforcement Eying Open Payments Compliance
Aug 27, 2021
PhRMA Revises Code Guidelines on Speaker Programs
Aug 20, 2021
OPDP Issues Untitled Letter Over Alleged Lack of Risk Information in Sponsored Links
Aug 13, 2021
OPDP Researchers Announce Completion of HCP Survey
Aug 10, 2021
Oregon To Require Drug Sales Rep. Licensing
Aug 2, 2021
After Six Years, FDA Finalizes Rule on the Evidence Used To Determine the Intended Uses of Devices
Jul 30, 2021
OPDP Adds Three Topic-Based Questions to FAQs
Jul 23, 2021
State AGs Reach Settlement with J&J, Distributors
Jul 16, 2021
OPDP Issues Second Untitled Letter of 2021

Good Clinical Practice

Nov 5, 2021
BMJ Investigation Alleges Problems at Three Clinical Sites in Pivotal COVID-19 Vaccine Trial
Oct 29, 2021
BIMO Inspection 483s Increase by a Third in FY 2021
Oct 28, 2021
FDA Warning Letter Alleges Investigator Failed To Follow Investigational Plan for Clinical Trial
Oct 28, 2021
HHS OIG: Medicare Co-Pay Subsidies for Alzheimer’s Disease Study Subjects Would Not Trigger Sanctions
Oct 20, 2021
Two Sponsor-Investigators Issued Warning Letters for Failing To Submit INDs
Oct 14, 2021
FDA Issues Warning Letter to Second Sponsor for Failing to Submit INDs
Oct 1, 2021
FDA Issues Draft Guidance on Investigator Responsibilities Regarding Safety Reporting
Sep 29, 2021
FDA Rejects Study Data from Two Labs in India
Sep 17, 2021
FDA Issues Sponsor-Investigator Notice for Not Posting Results
Sep 10, 2021
Trial Sponsor Receives Warning Letter over Investigational Product FDA Considers Drug, Not Food

U.S. Food Labeling

May 13,2020
AMS Extends Sunset Date of Various Substances on Organic Substances List
Apr 30,2020
FDA Extends Comment Period on Principles for Food Standards Modernization
Apr 16,2020
FSIS Says Product of USA Labeling May Be ‘Confusing,’ Will Initiate Rulemaking
Apr 2,2020
FDA, FSIS Offer Labeling Flexibilities in Response to COVID-19
Mar 18,2020
FSIS Reaffirms Consistent Use of ‘Healthy’ Claims as Allowed by FDA
Mar 16,2020
FDA Initiates Educational Campaigns on Nutrition Labeling, GMO Food
Mar 16,2020
FDA Sends CBD Report to Congress That Fails To Give Specifics on Moving Forward
Mar 12,2020
Interest Group, Others Sue USDA Over ‘Organic’ Certification for Hydroponics
Mar 7,2020
Labeling Violations Cited in Warning Letter
Mar 7,2020
Survey Results Show Consumer Confusion About Plant-based Meat Products

FDA Regulation & Enforcement

Sep 15, 2024
AbbVie Receives Untitled Letter Over Ubrelvy TV Ad
Sep 11, 2024
Device Maker To Pay $700K To Resolve Allegations of Encouraging Use of Incorrect Billing Codes
Sep 10, 2024
FSIS Updates Substantiation Guidance for Animal-Raising and Environmental Label Claims
Aug 28, 2024
DOJ Adds Conspiracy, Fraud Charges Against Biolab Operator Who Allegedly Sold Illegal COVID-19 Tests
Aug 28, 2024
CEO of Stem Cell Product Manufacturing Firm Pleads Guilty to Felony Distribution of Unapproved Drug
Aug 27, 2024
FDA Promises FOPL NPRM in October, Final Rule on ‘Healthy’ Definition in September
Aug 23, 2024
FTC Approves Final Rule on Product Reviews and Testimonials
Aug 23, 2024
FDA Moves to Phase II of Its Sodium Reduction Program
Aug 21, 2024
Pharma Distributor Urges Supreme Court Not To Hear Case Seeking Interpretation of Anti-Kickback Statute
Aug 16, 2024
Appeals Court Rejects Challenge to USDA’s Decision on Poultry Labeling

Medical Devices

Copyright © Thompson FDA, a division of CBIS. All rights reserved.